Orchard Therapeutics (ORTX) was founded in 2015 and has been dedicated to advancing gene therapies for ultra-rare diseases. In 2018, they acquired GSK’s portfolio of gene therapies and became a public company. Orchard now has one of the most extensive and advanced pipelines in the gene therapy space. They have proven that their technology is effective, safe and durable. One of the scientific cofounders has taken on the CEO role and has initiated a new strategic plan to transition Orchard to a successful commercial stage company. Shares are trading near a 52-week low